MGC Pharmaceuticals Limited First patient enrolled in MGC ZAM App (0405T)
March 15 2023 - 2:00AM
UK Regulatory
TIDMMXC
RNS Number : 0405T
MGC Pharmaceuticals Limited
15 March 2023
MGC Pharmaceuticals Ltd.
First patient enrolled in MGC ZAM App - CannEpil(R) Clinical
Trial
15 March 2023
ASX, LSE: MXC
MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a
European based pharmaceutical company specialising in the
production and development of plant inspired medicines, has
enrolled the first patient in the Company's proprietary d ata
collection App and machine learning algorithm, ZAM, and will log
the data from the commencement of an observational study monitoring
the effects of MGC Pharma's epilepsy treatment, CannEpil(R).
The app will record daily metrics from patients, their symptoms,
and the impact of their treatment in order to establish a baseline.
This will provide both medical practitioners and MGC Pharma with a
detailed record of the study and an enhanced understanding of the
effect of CannEpil(R) on Refractory Epilepsy patients.
The App will not only provide the patients with reminders on how
and when to take medication (per their medical practitioners'
advice), but will also measure treatment progress, and have the
ability for a qualified doctor to prescribe alternative medication
following a consultation.
The trial is supported by the "I am Billy" Foundation, a charity
set up to aid parents and families in navigating the challenges of
obtaining NHS-funded Medical Cannabis for children.
Roby Zomer, co-founder and Managing Director of MGC
Pharmaceuticals, commented : "The enrolment of the first patient in
the ZAM App in the UK, enables us to fully record the impact and
efficacy of our products undergoing trials. Consolidation of data
is of paramount importance in ensuring the safety and efficiency of
MGC's proprietary products, and we see the integration of both
pharma and tech as a revolution in the clinical trial process.
"We are proud to be supporting the "I am Billy" foundation in
this endeavour, and are pleased to be recognised as a leading
company in the sector."
Authorised for release by the board of directors, for further
information please contact:
MGC Pharmaceuticals Ltd MGC Pharmaceuticals Ltd
Roby Zomer Arron Canicais & Rowan Harland
CEO & Managing Director Company Secretary
+61 8 6382 3390 +61 8 6382 3390
info@mgcpharma.co.uk info@mgcpharma.co.uk
UK Financial and Corporate UK PR Advisors
Advisor Tavistock
SW4 Partners Charles Vivian / Tim Pearson
Rupert Fane / Nilesh Patel +44 207 920 3150
+44 7810 056 104 mgcpharma@tavistock.co.uk
rupert@sw4partners.com / nilesh@sw4partners.com
About I am Billy
I am Billy is a foundation set up to aid parents and families in
navigating the challenges of obtaining NHS-funded Medical Cannabis
for children. The foundation provides financial assistance in
meeting the cost of cannabis based medical products (CBMPs)
prescribed by a medical consultant, in addition to advancing the
public understanding of the medical benefits of CBMPs.
About MGC Pharma
MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying
accessible and ethically produced plant inspired medicines,
combining in-house research with innovative technologies, with the
goal of finding or producing treatments to for unmet medical
conditions.
The Company's founders and executives are key figures in the
global pharmaceuticals industry and the core business strategy is
to develop and supply high quality plant inspired medicines for the
growing demand in the medical markets in Europe, North America and
Australasia.
MGC Pharma has a robust development pipeline targeting two
widespread medical conditions and has further products under
development.
MGC Pharma has partnered with renowned institutions and academia
to optimise the development of targeted plant inspired medicines,
to be produced in the Company's EU-GMP Certified manufacturing
facilities.
MGC Pharma has a growing patient base in Australia, the UK,
Brazil, and Ireland and has a global distribution footprint via an
extensive network of commercial partners meaning that it is poised
to supply the global market.
Follow us through our social media channels:
Twitter: @MGC_Pharma
Facebook: @mgcpharmaceuticals
LinkedIn: MGC Pharmaceuticals Ltd.
Instagram: @mgc_pharma
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDGPUGWWUPWUQA
(END) Dow Jones Newswires
March 15, 2023 03:00 ET (07:00 GMT)
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From Apr 2024 to May 2024
Mgc Pharmaceuticals (LSE:MXC)
Historical Stock Chart
From May 2023 to May 2024